tradingkey.logo
搜尋

Harvard Bioscience Inc

HBIO
添加自選
6.050USD
-0.100-1.63%
收盤 07/01, 16:00美東報價延遲15分鐘
27.29M總市值
虧損本益比TTM

Harvard Bioscience Inc

6.050
-0.100-1.63%
查看詳細走勢圖
TradingKey 图表
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-1.63%

5天

-0.49%

1月

-5.47%

6月

-9.54%

今年開始到現在

-9.54%

1年

+1249.24%

關鍵數據
6.150今開
6.280最高
20.43K成交量
虧損本益比TTM
12.69本益比動
--股利TTM
0.45%換手率
6.150昨收
5.990最低
97.86K成交額
虧損本益比靜
2.72市淨率
0.00%股息率 TTM
-12.41%ROA
9.45852週最高
1.51量比
-12.40M淨利潤
4.51M總股本
-2.1224每股盈餘TTM
1.55Beta
-78.65%ROE
3.10152週最低
4.72%振幅
55.04%毛利率
27.29M總市值
-0.90回報/風險
5.31%風險率

TradingKey Harvard Bioscience Inc股票評分

單位: USD 更新時間: 2026-07-01

操作建議

Harvard Bioscience Inc當前公司基本面數據相對穩定,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名100/204位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為6.00。中期看,股價處於平穩狀態。近一個月,市場表現較差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Harvard Bioscience Inc評分

相關信息

行業排名
100 / 204
全市場排名
263 / 4564
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看好

Harvard Bioscience Inc亮點

亮點風險
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.
業績增長期
公司處於發展階段,最新年度總收入86.55M美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入86.55M美元
估值合理
公司最新PE估值-2.85,處於3年歷史合理位
機構減倉
最新機構持股2.44M股,環比減少15.49%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉0.00股

分析師目標

基於 2 分析師
買入
評級
6.000
目標均價
-2.44%
漲幅空間

Harvard Bioscience Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Harvard Bioscience Inc簡介

Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.
公司代碼HBIO
公司Harvard Bioscience Inc
CEODuke (John D)
網址https://www.harvardbioscience.com/

常見問題

Harvard Bioscience Inc(HBIO)的當前股價是多少?

Harvard Bioscience Inc(HBIO)的當前股價是 6.05。

Harvard Bioscience Inc 的股票代碼是什麼?

Harvard Bioscience Inc的股票代碼是HBIO。

Harvard Bioscience Inc股票的52週最高點是多少?

Harvard Bioscience Inc股票的52週最高點是9.46。

Harvard Bioscience Inc股票的52週最低點是多少?

Harvard Bioscience Inc股票的52週最低點是3.10。

Harvard Bioscience Inc的市值是多少?

Harvard Bioscience Inc的市值是27.29M。

現在Harvard Bioscience Inc(HBIO)的股票是買入、持有還是賣出?

根據分析師評級,Harvard Bioscience Inc(HBIO)的總體評級為買入,目標價格為6.00。

Harvard Bioscience Inc(HBIO)股票的每股收益(EPS TTM)是多少

Harvard Bioscience Inc(HBIO)股票的每股收益(EPS TTM)是-12.77。